Endometrial Cancer

Adavosertib demonstrated clinical activity among women with recurrent uterine serous carcinoma, according to results of a phase 2 study published in Journal of Clinical Oncology.

Researchers recently presented early data on the efficacy of chimeric antigen receptor T-cell therapy for diffuse midline gliomas during the virtual American Association for Cancer Research Annual Meeting.

The FDA granted accelerated approval to dostarlimab-gxly for treatment of certain women with endometrial cancer.

Postoperative systemic or radiation therapy did not extend survival for women with high-risk stage I endometrial cancer, according to results presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Interventions designed to improve care for Black women with endometrial cancer can help overcome clinical trial inequities, according to findings presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Treatment with a levonorgestrel-dispensing intrauterine device appeared to be effective and safe for women with stage I endometrial adenocarcinoma or endometrial hyperplasia with atypia, according to results of a randomized, phase 2 study.

Regionalization of care for high-grade endometrial cancer in Ontario had no negative effect on surgical wait times, according to findings presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Lenvatinib plus pembrolizumab improved outcomes vs. chemotherapy for women with advanced endometrial cancer, according to findings presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

High daily dietary cadmium intake appeared associated with shorter OS among women with endometrial cancer, according to study results published in Nutrition and Cancer.

James K. Aikins Jr., MD, FACOG, FACS, has been appointed chief of gynecologic oncology at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital.